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Abstract  
 
Parkinson’s disease (PD) is frequently compounded by neruropsychiatric complications, 
increasing disability. The combined effect of motor and mental status on care-dependency in 
PD outpatients is not well characterized. We conducted a cross-sectional study of 1449 PD 
outpatients. The assessment comprised the Montgomery-Asberg Depression Rating Scale 
(MADRS) and the diagnostic criteria for dementia. PD severity and treatment complications 
were rated using Hoehn and Yahr staging and the Unified Parkinson’s Disease Rating Scale 
(UPDRS) IV. The acknowledged level of care-dependency was documented. Care-
dependency was present in 18.3% of all patients. A total of 13.9% had dementia, 18.8% had 
depression, and 14.3% had both. Regression analyses revealed increasing effects of age, PD 
duration, and PD severity on care-dependency in all three mental-disorder subgroups with the 
strongest effects in patients with depression only. Depressed patients with antidepressive 
treatment still had significantly higher PD severity, higher MADRS and UPDRS-IV scores 
but were not more likely to be care-dependent than non-depressed patients. Older age, longer 
duration and increased severity of PD contribute to care-dependency in patients with 
untreated depression. Treatment of depression is associated with lower rates of care-
dependency.   
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1. Introduction  
 
Parkinson’s disease (PD) is a common neurodegenerative disorder among the elderly, 
characterized by progressing motor impairment leading to increasing physical disability [1]. It 
can also be accompanied by neuropsychiatric complications such as dementia or depression, 
aggravating the course of the disease in 25-50% of all patients [2, 3]. Both motor and 
neuropsychiatric aspects increase risk of care-dependency. However, while the effect of 
neuropsychiatric symptoms on care-dependency has been evaluated for patients with 
dementia without PD [4], the relationships among motor features, neuropsychiatric 
complications, and care-dependency in outpatients with PD have been neglected. Recent 
socioeconomic studies on PD patients have identified disease severity, dementia, and 
depression as substantial cost drivers in the course of the disease but have not investigated the 
direct links between these factors and care-dependency [5,6].  
 
Recently, we published results from a large representative sample of 1449 PD outpatients 
(German Study on the Epidemiology of Parkinson’s Disease with Dementia, GEPAD), 
providing an overview of the associations between neuropsychiatric symptoms in PD and 
care-dependency [7]. In the light of its amenability to various intervention strategies [8], we 
focus on the role of depression and its medicamentous treatment in the occurrence of care-
dependency in PD outpatients with and without dementia in this paper.  
 
 
2. Methods  
 
2.1. Study design  
 
The study design and materials of GEPAD have been described previously in greater detail 
[9]. In summary, GEPAD was a cross-sectional study involving 1449 outpatients with PD, 
randomly selected and clinically assessed by a nationwide representative sample of 315 
office-based neurologists on a single study day. The assessment comprised standardized 
instruments including the Montgomery-Asberg Depression Rating Scale (MADRS) and the 
diagnostic DSM-IV criteria for dementia, obtained in a structured clinical interview [10,11]. 
Based on the validation studies by Leentjens et al. [12], our study criteria for depression were 
either a MADRS total score ≥ 14 and/or current treatment with antidepressants. In this paper, 
we distinguish between patients with depression (study criteria for depression fulfilled, but no 
dementia present), dementia (study criteria for dementia met but not for depression), or both 
(study criteria for depression as well as DSM-IV criteria met). The physicians recorded the 
current treatment status. The severity of PD was rated according to the Hoehn and Yahr 
staging (HY) scale. Complications in PD treatment were documented using the Unified 
Parkinson’s Disease Rating scale (UPDRS) IV. For each patient, the physician noted the 
officially acknowledged level of care-dependency. In Germany, a patient’s level of care-
dependency is determined by an expert member of the Medical Service of the Central 
Association of Health Insurance Funds. It is defined using one of three severity grades: one = 
substantially care-dependent (average daily need for assistance at least 90 min, of which at 
least 45 min account for personal care such as bathing, feeding, assisting with toileting); two 
= severely care-dependent (average daily need for assistance at least 180 min, of which at 
least 120 min account for personal care); and three = most severely care-dependent (average 
daily need for assistance at least 300 min, of which at least 240 min account for personal care, 
and nocturnal assistance also becomes necessary). In this paper, care-dependency is defined 
as the presence of at least level one. In the absence of an officially acknowledged level of 
care-dependency, the physicians were also asked to state whether the patient nonetheless met 
criteria for care-dependency (but application pending or not made). In this paper, if not 
otherwise indicated, analyses on care-dependency only include patients with an officially 
acknowledged level.  
 
2.2. Statistics  
 
All scores (summary-scores and subscores) were calculated according to the corresponding 
scoring algorithms. Associations with 95% confidence intervals (CIs) of treatment status and 
PD severity and care-dependency were analyzed by regression models among patients with 
and without a current depression symptomatology. Logistic regression models were applied 
for categorical data and linear regression models for continuously distributed data. The 
predictive value of age, duration of PD and PD severity for care-dependency was investigated 
by considering the area under the receiver operating characteristics curve (AUC). Statistical 
inference was based on a significance level of 5%. For standard errors, CI, and /P/ values, the 
Huber-White sandwich estimator was implemented to take the clustered sampling design of 
the study into account [13]. For the detection of differences in metric and nonparametric data, 
we used the t-test and the Mann-Whitney test, respectively.  
 
2.3. Ethics  
 
The study was approved by the local Ethics Committee (August 11, 2005, No. 
EK140082005). Written informed consent was obtained from all participating patients or their 
caregivers.  
 
 
3. Results  
 
3.1. Study population  
 
The majority of patients was male (60.5%) and had a mean age of 70.7 ± 8.4 years, with a 
mean PD duration of 5.5 5.1 years. According to the HY stages, 44.2% of all patients had 
mild PD (HY I + II), 38.7% had moderate PD (HY III), and 17.1% suffered from severe PD 
(HY IV + V). Regarding mental status, 13.9% had dementia, 18.8% met study criteria for 
depression (of which 7.3% scored MADRS ≤ 13 but were currently treated with 
antidepressants), and 14.3% suffered concurrently from both disorders (i. e. dementia total: 
28.2%, depression total: 33.1%). At the time of study conduction, 24.5% of all demented 
patients received antidementia treatment (acetylcholine esterase inhibitors, ChE-I).  
 
A level of care-dependency was acknowledged for 18.3% of all patients (n = 266 of 1449), of 
which the majority either had level one (51.9%, n= 138) or level two (43.2%, n= 115), 
respectively. Thirteen patients (4.9%) had level three. One-hundred twenty-one (8.5%) 
patients had no officially acknowledged level of care-dependency but met criteria for care-
dependency according to their attending clinicians. For 22 patients, information on care-
dependency status was not available to the physician; however, they did not differ from care-
independent patients (i.e., no care-dependency level acknowledged and criteria not met) 
regarding age (P= 0.951), HY-staging (P= 0.311), or frequency of dementia (P =0.109) or 
depression (P = 0.250).  
 
Care-dependency occurred more frequently in patients aged ≥76 years (43.3%) than in 
patients at the age of 66-75 (23.7%) or ≤65 (13.9%), respectively. The mean (±SD) MADRS 
score increased significantly with advancing levels of care-dependency, ranging from 7.7 ± 
6.8 (“none”) to 13.1 ± 8.3 (“one”), 14.3 ± 9.6 (“two”) and 18.5 ± 11.3 (“three”, total group 
differences P < 0.001).  
 
3.2. Predictors for care-dependency  
 
We used a multiple stepwise logistic regression model to calculate the effect of age, PD 
duration, and PD severity on caredependency. We first entered age, added PD duration (step 
two), and finally entered PD severity (step three). Results are displayed in Fig. 1.  
 
In all three mental-disorder subgroups, the stepwise entry of the predictors substantially 
increased the AUCs. The largest AUCs were seen in patients with depression (AUCs: 0.681, 
0.739, and 0.818), and the smaller in patients with dementia (AUCs: 0.603, 0.687, and 0.797) 
or both disorders combined (AUCs: 0.616, 0.642, and 0.782).  
 
3.3. Depression treatment and care-dependency  
 
Table 1 shows the associations among care-dependency, PD severity, PD treatment 
complications (UPDRS-IV), and depression, stratified by depression treatment status. 
Regardless of whether they were treated for depression or not, patients with a MADRS score 
≥ 14 had more severe PD, experienced more treatment complications, and were more 
frequently care-dependent than patients with a MADRS score ≤ 13. Among patients below 
this cut-off for depression, patients who underwent antidepressive treatment were not more 
care-dependent (P =0.794) than the non-depressed PD group, although the former had higher 
HY stages (P <0.05), more treatment complications (P< 0.05), and higher MADRS scores (P 
< 0.01). In terms of ORs, these patients had an insignificant OR for care-dependency (OR= 
1.1, 95% CI: 0.66-1.73) compared to non-depressed patients. This lack of significance still 
held true after adjustment for dementia (18.8% vs. 23.9%, OR= 1.1, 95% CI: 0.68-1.81). 
These effects also applied to patients without an officially acknowledged level of care-
dependency but who met the criteria for care-dependency according to the clinician (OR= 1.0, 
95% CI: 0.51-2.08 and OR =1.1, 95% CI: 0.52-2.14 after adjustment for dementia).  
 
 
4. Discussion  
 
In this paper, we analyzed the associations among PD, neuropsychiatric complications, and 
the degree of care-dependency, based on a large and representative sample of outpatients in 
Germany. According to the study criteria for dementia and depression, a large proportion of 
patients suffered from at least one of the disorders (47%). About one in three patients (33.1%) 
met the study criteria for depression.  
 
Two important findings emerged from this work. First, in all three mental-disorder subgroups 
(depression, dementia, or both) age, duration of PD, and PD severity were clearly associated 
with care-dependency. PD severity contributed most to care-dependency, considerably 
increasing the AUCs at final entry in each subgroup. In patients with depression (but no 
dementia), the effects turned out to be strongest, revealing the largest AUCs when stepwise 
entering the variables considered. Thus, in these patients, care-dependency is driven more by 
these variables – especially age – than in patients with dementia (with and without 
concomitant depression).  
 
Second, successfully treated (with antidepressants) subsyndromal patients (i.e., scoring below 
the MADRS cut-off for major depression while taking antidepressants) still experienced more 
severe motor impairments, more PD treatment complications, and higher MADRS scores than 
non-depressed patients. However, they were not more frequently care-dependent. This 
outcome was largely independent from the concurrent presence of dementia. In patients with 
dementia, the rates of care-dependency were increased overall, but the proportions and level 
of significance remained the same.  
 
Our data underscore that dementia and depression are important contributors to the overall 
disease burden in PD, as previously reported [5,6,14]. In addition, the GEPAD results 
highlight the substantial effect of depression on care-dependency in PD, suggesting that drug 
therapy for depression in PD with and without dementia is always beneficial because it 
reduces the personal burden of the patients.  
 
Our findings, however, should be interpreted cautiously because of a number of 
methodological limitations. First, it is important to note that the acknowledgment of care-
dependency in Germany is mainly based on a person’s incapacity to perform basic physical 
actions. Incapacities that result from neuropsychiatric complications and that usually increase 
the need for time-consuming assistance in everyday life are often taken inadequately into 
account. They lead, however, to a substantial degree of disability, especially for patients with 
mild to moderate dementia. Thus, the officially acknowledged care-dependency in our sample 
probably underestimates the real dependency on assistance, which relatives usually provide. 
Second, our results might be biased by the use of a screening tool for depression only instead 
of a comprehensive interview; however, because of feasibility concerns, we wanted to keep 
the assessment simple for the participating physicians. We are therefore unable to provide 
more sophisticated data on the type of depression or on previous episodes of depressive 
disorders. By the same token, we have not implemented a diagnostic instrument for the 
assessment of anxiety disorders, which are a frequent accompaniment of depression, and can 
equally contribute to care-dependency. Third, it should be noted that our analyses of 
associations between PD severity and CDP are limited by the use of the coarse-grained HY-
staging instead of more sophisticated analyses based upon the UPDRS motor subscale. 
However, the latter one could not be implemented to the study protocol for logistical reasons, 
as it would have considerably prolonged the duration of assessment. Thus, to keep the study 
feasible for the participating office-based physicians (and their patients) during their daily 
routine care, we decided to omit the UPDRS III. By the same token, we lack further details 
regarding the patients’ dementia status (e. g. duration, age at onset), as well as more detailed 
data about further neuropsychiatric conditions that might also contribute to care-dependency, 
such as anxiety disorders or psychotic syndromes. Similarly, the comprehensive 
documentation of these conditions would have required a considerably extended assessment. 
Finally, it should be considered that the prescription of antidepressants is not always a valid 
indicator for depression because these medications can also be prescribed for other medical 
conditions such as sleep disorders. However, it is noteworthy that in the GEPAD sample, the 
corresponding subgroup of patients featured characteristics that are rather typical for sub-
syndromal patients but not for non-depressed patients (i.e., still significantly higher MADRS 
scores, more treatment complications and motor impairments) [15]. In any case, more detailed 
studies are certainly needed to develop a deeper understanding of PD, neuropsychiatric 
symptoms, care-dependency, and mediating factors.  
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